Real-world study of olaparib for prostate cancer
Part of Cancer clinical trials.
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult male aged 18 or older
- You have metastatic castration-resistant prostate cancer (cancer that has spread and no longer responds to hormone therapy)
- You have started taking olaparib at least two months ago as part of your regular care or through a special early access program
- You are okay with your medical data being used for this research (if you have passed away, you didn't say no to your data being used for research)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced prostate cancer (mCRPC) who are already taking the combination of olaparib and abiraterone. It will look at how these two medicines work together in real-world practice.
This trial uses a blood test (circulating tumor DNA) to see whether PARP inhibitors are working for certain men with advanced prostate cancer. It may help predict which treatment responses are likely and monitor changes over time.
This trial studies how well olaparib works for men with metastatic castration-resistant prostate cancer that has a BRCA mutation. It looks at results from real-world use, not a controlled study.
This trial studies how well the combination of olaparib and abiraterone works for men with advanced prostate cancer that has stopped responding to hormone therapy. If you are already taking or planning to take this combination, researchers want to learn more about its long-term benefits and safety.
This Phase 2 study tests whether carboplatin or olaparib can help people with prostate cancer that has certain DNA repair gene changes. It’s designed for advanced (metastatic) prostate cancer that is growing despite standard hormone-blocking treatment.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.